Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 2, 2008, Pages 271-283

  Têtu, Bernard ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

androgen blockade; drug effects; drug therapy; hormone therapy; pathology; prostate; prostate cancer; prostatectomy; prostatic neoplasms

Indexed keywords

ALPHA TOCOPHEROL; ANTIANDROGEN; CYPROTERONE ACETATE; CYTOKERATIN; ESTRAMUSTINE PHOSPHATE; FINASTERIDE; GONADORELIN AGONIST; GREEN TEA EXTRACT; KI 67 ANTIGEN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SELENIUM; SOYBEAN PROTEIN; VITAMIN D;

APOPTOSIS; CANCER CELL; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL ACTIVITY; CELL CLONE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MALE; MORPHOLOGY; ORCHIECTOMY; PREVALENCE; PROSTATE CARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 42949108205     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.01.005     Document Type: Review

References (61)

1. Fair W.R., Aprikian A., and Reuter V. Neoadjuvant hormonal manipulation: a strategy for chemoprevention trials. Journal of Cellular Biochemistry. Supplement 16H (1992) 118-121
2. Scott W.W., Menon M., and Walsh P.C. Hormonal therapy of prostatic cancer. Cancer 45 (1980) 1929-1936
3. Lukka H., Waldron T., Klotz L., et al. Maximal androgen blockade for the treatment of metastatic prostate cancer-a systematic review. Current Oncology 13 (2006) 81-93
4. Fleshner N., and Zlotta A.R. Prostate cancer prevention: past, present, and future. Cancer 110 (2007) 1889-1899
5. Meyer F., Bairati I., Bedard C., et al. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer. Urology 58 (2001) 71-77
6. Sarosdy M.F., Schellhammer P.F., Johnson R., et al. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?. Urology 55 (2000) 391-395
7. D'Amico A.V., Renshaw A.A., Loffredo B., et al. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 110 (2007) 1723-1728
8. Vaillancourt L., Têtu B., Fradet Y., et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. American Journal of Surgical Pathology 20 (1996) 86-93
9. Armas O.A., Aprikian A.G., Melamed J., et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. American Journal of Surgical Pathology 18 (1994) 979-991
10. Civantos F., Marcial M.A., Banks E.R., et al. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 75 (1995) 1634-1641
11. Murphy W.M., Soloway M.S., and Barrows G.H. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68 (1991) 821-828
12. Têtu B., Srigley J.R., Boivin J.C., et al. Effect of combination endocrine therapy (LHRH Agonist and Flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. American Journal of Surgical Pathology 15 (1991) 111-120
13. van der Kwast T.H., Têtu B., Fradet Y., et al. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate 28 (1996) 227-231
14. van der Kwast T.H., Têtu B., Suburu E.R., et al. Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. The Journal of Pathology 186 (1998) 406-409
15. Witjes W.P.J., Schulman C.C., and Debruyne F.M.J. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. Urology 49 (1997) 65-69
16. Labrie F., Cusan L., Gomez J., et al. Neoadjuvant hormonal therapy : the Canadian experience. Urology 49 (1997) 56-64
17. Bono A.V., Pagano F., Montironi R., et al. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study. Urology 57 (2001) 117-121
18. Fair W.R., Cookson M.S., Stroumbakis N., et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 49 (1997) 46-55
19. Amling C.L., Blute M.L., Bergstralh E.J., et al. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Seminars in Urologic Oncology 15 (1997) 222-229
20. van der Kwast T.H., Têtu B., Candas B., et al. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology 53 (1999) 523-529
21. Hellström M., Ranefall P., Webster K., et al. Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer. British Journal of Urology 79 (1997) 421-426
22. Gleave M.E., Goldenberg S.L., Jones E.C., et al. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. The Journal of Urology 155 (1996) 213-219
23. Têtu B. Morphologic changes induced by neoadjuvant combination hormone therapy on prostatic tissue and prostate cancer. Endocrine-Related Cancer 3 (1996) 165-170
24. Maldonado-Valadez R., Teber D., Erdogru T., et al. The impact of neoadjuvant hormonal therapy on the outcome of laparoscopic radical prostatectomy: a matched pair analysis. The Journal of Urology 175 (2006) 2092-2096
25. Soloway M.S., Sharifi R., Wajsman Z., et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Journal of Urology 154 (1995) 424-428
26. Bazinet M., Zheng W., Begin L.R., et al. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 49 (1997) 721-725
27. Gleave M.E., Goldenberg S.L., Chin J.L., et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. The Journal of Urology 166 (2001) 500-506
28. Schulman C.C., Debruyne F.M., Forster G., et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. European Urology 38 (2000) 706-713
29. Ohori M., Wheeler T.M., Kattan M.W., et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. The Journal of Urology 154 (1995) 1818-1824
30. Epstein J.I., Pizov G., and Webster K. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71 (1993) 3582-3593
31. Catalona W.J., and Avioli L.V. Diagnosis, staging, and surgical treatment of prostatic carcinoma. Archives of Internal Medicine 147 (1987) 361-363
32. Stamey T.A., McNeal J.E., Freiha F.S., et al. Morphometric and clinical studies on 68 consecutive radical prostatectomies. The Journal of Urology 139 (1988) 1235-1241
33. Tran T.A., Jennings T.A., Ross J.S., et al. Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy. American Journal of Surgical Pathology 22 (1998) 347-354
34. Smith D.M., and Murphy W.M. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer 73 (1994) 1472-1477
35. Hellstrom M., Haggman M., Brandstedt S., et al. Histopathological changes in androgen-deprived localized prostatic cancer. A study in total prostatectomy specimens. European Urology 24 (1993) 461-465
36. Kaltz-Wittmer C., Klenk U., Glaessgen A., et al. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Laboratory Investigation 80 (2000) 1455-1464
37. Osman I., Scher H.I., Drobnjak M., et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clinical Cancer Research 7 (2001) 2643-2647
38. Shi Y., Brands F.H., Chatterjee S., et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. The Journal of Urology 166 (2001) 1514-1519
39. Montironi R., Mazzucchelli R., Barbisan F., et al. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Human Pathology 37 (2006) 1137-1144
40. Montironi R., Magi-Galluzzi C., Muzzonigro G., et al. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. Journal of Clinical Pathology 47 (1994) 906-913
41. Montironi R., Magi-Galluzzi C., and Fabris G. Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathology Research and Practice 191 (1995) 873-880
42. Eble J.N., Sauter G., Epstein J.I., et al. Tumours of the urinary system and male genital organs. [Chapter 3, tumours of the prostate] (2004), WHO, Lyon
43. Van de Voorde W.M., Elgamal A.A., van Poppel H., et al. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. Cancer 74 (1994) 3164-3175
44. van der Kwast T.H., Schalken J., Ruizeveld de Winter J.A., et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. International Journal of Cancer 48 (1991) 189-193
45. Kruithof-Dekker I.G., Têtu B., Janssen P.J.A., et al. Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy. The Journal of Urology 156 (1996) 1194-1197
46. Labrie F., Cusan L., Gomez J., et al. Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy in localized prostate cancer. Molecular Urology 1 (1997) 253-261
47. Evans A.J., Humphrey P.A., Belani J., et al. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. American Journal of Surgical Pathology 30 (2006) 684-693
48. Ferguson F., Zincke H., Ellison E., et al. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 44 (1994) 91-95
49. van der Kwast T.H., Labrie F., and Têtu B. Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Human Pathology 30 (1999) 1503-1507
50. Grignon D., and Troster M. Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy. Prostate 7 (1985) 195-202
51. Helpap B. Treated prostatic carcinoma. Histological, immunohistochemical and cell kinetic studies. Applied Pathology 3 (1985) 230-241
52. van Poppel H., De Ridder D., Elgamal A.A., et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Journal of Urology 154 (1995) 429-434
53. Dhom G., and Degro S. Therapy of prostatic cancer and histopathologic follow-up. Prostate 3 (1982) 531-542
54. Dalkin B.L., Ahmann F.R., Nagle R., et al. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. The Journal of Urology 155 (1996) 1357-1360
55. Goldenberg S.L., Klotz L.H., Srigley J.R., et al. Randomized prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. The Journal of Urology 156 (1996) 873-877
56. Bullock M.J., Srigley J.R., Klotz L.H., et al. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. American Journal of Surgical Pathology 26 (2002) 1400-1413
57. Gleave M., Qian J., Andreou C., et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study. Prostate 66 (2006) 1674-1685
58. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. The New England Journal of Medicine 349 (2003) 215-224
59. Lucia M.S., Epstein J.I., Goodman P.J., et al. Finasteride and high-grade prostate cancer in the prostate cancer prevention trial. Journal of National Cancer Institute 99 (2007) 1375-1383
60. Thompson I.M., Lucia M.S., Redman M.W., et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. The Journal of Urology 178 (2007) 107-109
61. Aus G., Abrahamsson P.A., Ahlgren G., et al. Hormonal treatment before radical prostatectomy: a 3-year followup. The Journal of Urology 159 (1998) 2013-2016